Kevin Schultz is Chief Scientific Officer at Kindred Biosciences, Inc. (KIN). They have made 1 open-market trade across 1 company since 2013, most recently 2013-12-12.
CIK 0001593868
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $28K since 2013, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KIN | 4,000 | $37K |
Shares reported on the most recent Form 4, priced at the 2013-12-13 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KIN | BUY | 2013-12-12 | 2013-12-13 | $7.00 | $28K | -3.8% | +2.6% | +2.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.